The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Elizabeth Ann Mittendorf
No relevant relationships to disclose
Erika J Schneble
No relevant relationships to disclose
Sonia A. Perez
No relevant relationships to disclose
James T Symanowski
Consultant or Advisory Role - Antigen Express
Ritesh Patil
No relevant relationships to disclose
Timothy J. Vreeland
No relevant relationships to disclose
John S. Berry
No relevant relationships to disclose
Alfred F Trappey
No relevant relationships to disclose
Guy T. Clifton
No relevant relationships to disclose
Eric von Hofe
Employment or Leadership Position - AntiCen Express
Alexandros Ardavanis
No relevant relationships to disclose
Sathibalan Ponniah
No relevant relationships to disclose
Nathan M. Shumway
No relevant relationships to disclose
Michael Papamichail
No relevant relationships to disclose
George Earl Peoples
Consultant or Advisory Role - Antigen Express